ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ)
$2.45 0.03 (1.2397%)
Analysed ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) News Sources
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
18-06-2025
yahoo.com
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
23-06-2025
yahoo.com
Ziopharm: Q2 Earnings Snapshot
14-08-2025
yahoo.com
Ziopharm: Q3 Earnings Snapshot
14-11-2025
yahoo.com
Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders
02-03-2026
yahoo.com
Valion Bio Appoints Melinda Lackey as General Counsel
04-05-2026
yahoo.com
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models
18-05-2026
yahoo.com
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
26-05-2026
yahoo.com
Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers
26-05-2026
stocktwits.com
What is the current price of ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ)?
The current price of ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) is $2.45.
ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) since the previous trading day is $0.03.
ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) since the previous trading day is 1.2397%.
What is the most recent average sentiment score for ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ)?
The most recent average sentiment score for ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) is 55 out of 100.
What is the most recent average sentiment for ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ)?
The most recent sentiment for ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ) is .
SEC-8K** Filing Available For ALAUNOS THERAPEUTICS INC (TCRT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.